Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Asset Writedowns and Impairment: 2015-2024

Historic Asset Writedowns and Impairment for Coherus Oncology (CHRS) over the last 1 years, with Dec 2024 value amounting to $7.4 million.

  • Coherus Oncology's Asset Writedowns and Impairment fell 84.72% to $7.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $63.8 million, marking a year-over-year increase of 21.39%. This contributed to the annual value of $14.1 million for FY2024, which is 73.11% down from last year.
  • As of Q4 2024, Coherus Oncology's Asset Writedowns and Impairment stood at $7.4 million, which was up 8.85% from $6.8 million recorded in Q1 2024.
  • Coherus Oncology's Asset Writedowns and Impairment's 5-year high stood at $48.2 million during Q4 2023, with a 5-year trough of -$347,000 in Q2 2023.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $6.8 million (2024), whereas its average is $13.2 million.
  • As far as peak fluctuations go, Coherus Oncology's Asset Writedowns and Impairment skyrocketed by 400.00% in 2022, and later plummeted by 94.33% in 2023.
  • Over the past 4 years, Coherus Oncology's Asset Writedowns and Impairment (Quarterly) stood at -$59,000 in 2021, then skyrocketed by 400.00% to $26.0 million in 2022, then slumped by 94.33% to $48.2 million in 2023, then crashed by 84.72% to $7.4 million in 2024.
  • Its Asset Writedowns and Impairment was $7.4 million in Q4 2024, compared to $6.8 million in Q1 2024 and $48.2 million in Q4 2023.